ESTRO 2024 - Abstract Book

S2597

Clinical - Urology

ESTRO 2024

2975

Digital Poster

UHRT in PCa: a clinical and toxicity impact analysis from real world experience.

Chiara Lorubbio 1,2 , Ilaria Repetti 1,2 , Giulia Corrao 1 , Federico Mastroleo 1 , Maria Giulia Vincini 1 , Mattia Zaffaroni 1 , Cristiana Fodor 1 , Vanessa Pierini 1,2 , Giovanni Carlo Mazzola 1 , Cristiana Pedone 1,2 , Dario Zerini 1 , Giulia Marvaso 1 , Barbara Alicja Jereczek-Fossa 1,2 1 European Institute of Oncology, Division of Radiation Oncology, Milan, Italy. 2 University of Milan, Department of Oncology and Hemato-oncology, Milan, Italy

Purpose/Objective:

Randomized clinical trials have demonstrated the non-inferiority of ultra-hypofractionated radiotherapy (UHRT) compared to conventional RT in patients with localized prostate cancer (PCa). Despite an increased cost effectiveness and expanded RT access, UHRT adoption remains variable. Notwithstanding, patients with high percentage of comorbidities often are not considered for this approach, thus denying a curative treatment option. The aim of the present study is to evaluate the oncological outcomes, the toxicity profiles of a real world cohort of PCa patients who underwent curative UHRT +/- a simultaneous integrated boost (SIB) on dominat intraprostatic lesion(s) (DIL) +/- androgen deprivation therapy (ADT) and to assess the influence of pre-treatment Charlson Comorbidity Index (CCI) on acute and late RT-related side-effects.

Material/Methods:

Patients with localized PCa who underwent radical ultra-hypofractionated (UHRT) in a single institute were retrospectively included. Risk groups were determined based on NCCN definitions. For all patients age adjusted Charson Comorbidity Index (CCI) was calculate at baseline. After treatment, PSA was assessed every 3 months and biochemical progression (BP) was stated according to Phoenix definition. Clinical progression (CP) was evaluated as the presence of local or distant metastasis at radiological imaging. Maximum acute and late gastrointestinal (GI) and genitourinary (GU) toxicity were collected according to RTOG scale. The impact of CCI on the acute and late toxicities was explored. Patients were stratified according to CCI into 5 subgroups. Chi square test was performed to test any association among CCI and reported toxicities. All patients signed an informed consent for research purpose. This study was approved by local Ethical Committee (UID 2684).

Results:

From 2012 to 2022, a total of 824 patients matched included criteria. General cohort characteristics are reported in Table 1 . Median age at diagnosis was 76 years (IQR 71 - 80) and median iPSA was 7.3 ng/ml (IQR 5.14 – 10.30).